BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 26583156)

  • 1. Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.
    Goyvaerts C; Breckpot K
    J Immunol Res; 2015; 2015():785634. PubMed ID: 26583156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells for specific cancer immunotherapy.
    Meidenbauer N; Andreesen R; Mackensen A
    Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
    Reardon DA; Mitchell DA
    Semin Immunopathol; 2017 Feb; 39(2):225-239. PubMed ID: 28138787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
    H Yi D; Appel S
    Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
    Strioga MM; Darinskas A; Pasukoniene V; Mlynska A; Ostapenko V; Schijns V
    Vaccine; 2014 Jul; 32(32):4015-24. PubMed ID: 24837511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell-based nanovaccines for cancer immunotherapy.
    Paulis LE; Mandal S; Kreutz M; Figdor CG
    Curr Opin Immunol; 2013 Jun; 25(3):389-95. PubMed ID: 23571027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application.
    Trevor KT; Cover C; Ruiz YW; Akporiaye ET; Hersh EM; Landais D; Taylor RR; King AD; Walters RE
    Cancer Immunol Immunother; 2004 Aug; 53(8):705-14. PubMed ID: 15048588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.
    Jeanbart L; Ballester M; de Titta A; Corthésy P; Romero P; Hubbell JA; Swartz MA
    Cancer Immunol Res; 2014 May; 2(5):436-47. PubMed ID: 24795356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.
    Salem ML
    Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coupled for cross-presentation in tumor immunotherapy.
    Pang B; Neefjes J
    Sci Transl Med; 2010 Aug; 2(44):44ps40. PubMed ID: 20702855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic Cell-Based Cancer Vaccines.
    Santos PM; Butterfield LH
    J Immunol; 2018 Jan; 200(2):443-449. PubMed ID: 29311386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA-based dendritic cell vaccines.
    Benteyn D; Heirman C; Bonehill A; Thielemans K; Breckpot K
    Expert Rev Vaccines; 2015 Feb; 14(2):161-76. PubMed ID: 25196947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in dendritic cell-based vaccine of cancer.
    Zhang X; Gordon JR; Xiang J
    Cancer Biother Radiopharm; 2002 Dec; 17(6):601-19. PubMed ID: 12537664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
    Aikins ME; Xu C; Moon JJ
    Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of dendritic cell therapy for cancer: progress and challenges.
    Mantia-Smaldone GM; Chu CS
    BioDrugs; 2013 Oct; 27(5):453-68. PubMed ID: 23592406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ReNAissanCe of mRNA-based cancer therapy.
    Van Lint S; Renmans D; Broos K; Dewitte H; Lentacker I; Heirman C; Breckpot K; Thielemans K
    Expert Rev Vaccines; 2015 Feb; 14(2):235-51. PubMed ID: 25263094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell preparation for immunotherapeutic interventions.
    Simon T; Fonteneau JF; Grégoire M
    Immunotherapy; 2009 Mar; 1(2):289-302. PubMed ID: 20635946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunology in medical practice. XXV. Use of dendritic cells in the immunotherapy of cancer].
    Punt CJ; de Vries IJ; Mulders PF; Adema GJ; Figdor CG
    Ned Tijdschr Geneeskd; 1999 Nov; 143(48):2408-14. PubMed ID: 10608974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.